Bio-Path Holdings, Inc. (NASDAQ:BPTH) shares shot up 15.2% on Thursday . The stock traded as high as $0.39 and last traded at $0.38. 761,736 shares changed hands during mid-day trading, an increase of 29% from the average session volume of 592,400 shares. The stock had previously closed at $0.33.

Several brokerages recently weighed in on BPTH. HC Wainwright set a $5.00 target price on Bio-Path Holdings and gave the stock a “buy” rating in a research report on Friday, August 11th. Zacks Investment Research lowered Bio-Path Holdings from a “buy” rating to a “hold” rating in a research report on Wednesday, July 12th. Finally, ValuEngine lowered Bio-Path Holdings from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st.

The stock’s market cap is $41.02 million. The firm has a 50-day moving average of $0.31 and a 200 day moving average of $0.50.

Bio-Path Holdings (NASDAQ:BPTH) last issued its earnings results on Thursday, August 10th. The company reported ($0.03) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.01). On average, equities research analysts predict that Bio-Path Holdings, Inc. will post ($0.08) earnings per share for the current fiscal year.

Several large investors have recently modified their holdings of BPTH. Tower Research Capital LLC TRC acquired a new stake in shares of Bio-Path Holdings during the 1st quarter valued at $105,000. Bank of New York Mellon Corp boosted its stake in shares of Bio-Path Holdings by 1.7% during the 1st quarter. Bank of New York Mellon Corp now owns 311,645 shares of the company’s stock valued at $257,000 after buying an additional 5,172 shares during the period. HighTower Advisors LLC boosted its stake in shares of Bio-Path Holdings by 0.3% during the 2nd quarter. HighTower Advisors LLC now owns 1,267,070 shares of the company’s stock valued at $492,000 after buying an additional 4,000 shares during the period. Sabby Management LLC boosted its stake in shares of Bio-Path Holdings by 3.5% during the 1st quarter. Sabby Management LLC now owns 687,398 shares of the company’s stock valued at $569,000 after buying an additional 23,352 shares during the period. Finally, Legal & General Group Plc boosted its stake in shares of Bio-Path Holdings by 5,474.3% during the 2nd quarter. Legal & General Group Plc now owns 1,773,799 shares of the company’s stock valued at $681,000 after buying an additional 1,741,978 shares during the period. 15.16% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: “Bio-Path Holdings, Inc. (BPTH) Shares Up 15.2%” was published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another publication, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this piece can be accessed at https://www.watchlistnews.com/bio-path-holdings-inc-bpth-shares-up-15-2/1566272.html.

Bio-Path Holdings Company Profile

Bio-Path Holdings, Inc is a clinical and preclinical stage oncology focused antisense drug development company. The Company utilizes a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Its drug delivery and antisense technology, DNAbilize, is a platform that uses P-ethoxy, a deoxyribonucleic acid backbone modification.

Receive News & Ratings for Bio-Path Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path Holdings Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.